Current stock page

Stock Analysis

Nektar Therapeutics (NKTR) Stock Analysis

Nektar Therapeutics (NKTR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

NKTR Stock Analysis Summary

Nektar Therapeutics (NKTR) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 49/100. Momentum is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

NKTR at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$37.27
AIQ Score39/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$1.27B
P/E Ratio (TTM)-5.77
Forward P/E—
EPS (Q3 FY2026)-$1.63
Revenue (Q3 FY2026)$9.39M
Dividend Yield (TTM)0.00%
Beta1
Volume695.17K
52-week range$33.40-$109.00
RSI 1437.87
50-Day SMA$48.47
200-Day SMA$65.05
Analyst Price Target$95.75
Next EarningsMar 2, 2027
As of Nov 13, 2026 · Market close

NKTRNektar Therapeutics

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 1/10
$37.27+$0.02 (+0.05%)

Latest quote

  • Momentum
    25
  • Value
    47
  • Quality
    49
  • Risk resilience
    41
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

NKTR Stock Analysis Summary

Nektar Therapeutics (NKTR) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 49/100. Momentum is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, NKTR has AIQ Score of 39/100 with Quality base of 49/100 and fading Momentum at 25/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (49/100) leads while Momentum (25/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.05% stock move · NKTR classified in Biotechnology.

Current Evidence

BearishNKTR is in a bearish AIQ regime; Quality is the strongest visible factor at 49/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is NKTR Bullish or Bearish Right Now?

NKTR currently has a bearish overall setup. Quality is the strongest factor at 49/100, while Momentum is weakest at 25/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +156.91% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 47/100.
  • - Momentum is weak at 25/100.
  • - Risk Resilience is weak at 41/100.
  • - Price is -42.71% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (34 vs 3).

Current Consensus

NKTR's Technical Analysis Consensus is currently Strong Sell, with 3 buy, 9 neutral, and 34 sell votes. NKTR's 14-day RSI is 37.87, which places the stock in a weaker momentum range. NKTR's beta is 1, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in NKTR?

The largest recent change in NKTR is Quality moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-1.0
Momentum
+1.0
Quality
-8.0
Risk
+2.0

What Would Change the NKTR Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

NKTR Decision Framework

Public evidence layers, setup checks, and risk context for Nektar Therapeutics.

Nektar Therapeutics (NKTR) Stock Analysis

Nektar Therapeutics has an AIQ Score of 39/100 in a Bearish regime. Quality is strongest at 49/100. Beta is 1, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextNKTR is in a Bearish AIQ regime with score 39/100.
Signal ConflictThe primary conflict is that quality leads at 49/100 while momentum lags at 25/100.
Factor EvidenceMomentum 25/100 · Value 47/100 · Quality 49/100 · Risk 41/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthFail

Quality is the strongest factor at 49/100.

TimingFail

Momentum is 25/100 and RSI (14) is 37.9.

Regime fitFail

NKTR is in a Bearish regime at 39/100.

Risk controlFail

Risk factor is 41/100 with beta 1 and annual volatility 84.03%.

ConflictWait

Current conflict: quality leads at 49/100 while momentum lags at 25/100.

AIQ Score
39/100
Price
$37.27
Beta
1
RSI (14)
37.9

NKTR Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

NKTR Fundamentals

NKTR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$9.39M
Net income
-$55.65M
Free cash flow
-$72.33M
View full NKTR fundamental analysis

NKTR Technical Analysis

NKTR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
37.87
Price vs SMA-50
-23.11%
View full NKTR technical analysis

NKTR Stock Catalysts

Track NKTR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 2, 2027
Analyst target
$95.75
News items
5
View NKTR earnings and stock catalysts

NKTR Dividend Analysis

NKTR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View NKTR dividend history and analysis

NKTR Financial Data

NKTR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$9.39M
EPS
-$1.63
Periods
8
View NKTR financials

NKTR Risk Analysis

NKTR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1
Risk score
41/100
1Y volatility
84.03%
View NKTR risk analysis

NKTR Stock News

NKTR stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read NKTR stock news

NKTR vs Biotechnology Peers

Current peer cohort: NKTR · NRIX · NVAX · OCUL · OMER. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
NKTR
Current stock
39/10047/10025/10041/100-0.1184.03%Current
NRIX
Nurix Therapeutics, Inc.
65/10094/10050/10040/1000.6467.30%NKTR vs NRIX
NVAX
Novavax, Inc.
——77/10038/1000.5673.62%NKTR vs NVAX
OCUL
Ocular Therapeutix, Inc.
38/10041/10034/10036/100-0.4576.10%NKTR vs OCUL
OMER
Omeros Corporation
64/10073/10079/10033/1001.36110.84%NKTR vs OMER
Pairwise Compare links: NRIX · NVAX · OCUL · OMERNKTR vs NRIXNKTR vs NVAXNKTR vs OCULNKTR vs OMERCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a NKTR stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for NKTR: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-5.77
As of Nov 13, 2026
Revenue growth
-20.39%
Gross margin
-29.04%
Current debt / equity
0.09
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$9.39M
Quarter net income
-$55.65M
Quarter free cash flow
-$72.33M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
37.87
MACD
-2.58

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
41/100
Beta
1
Annual volatility
84.03%
Max drawdown
-64.34%

NKTR Stock FAQ

What is NKTR stock price today?

Nektar Therapeutics's current stock price is $37.27. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is NKTR bullish or bearish right now?

NKTR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is NKTR's market cap?

NKTR's market cap is $1.27B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is NKTR's current P/E ratio?

NKTR's current P/E ratio is -5.77 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is NKTR's RSI?

NKTR's 14-day RSI is 37.87 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is NKTR above its 50-day and 200-day moving averages?

NKTR is -23.11% from its 50-day SMA and -42.71% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is NKTR's next earnings date?

NKTR's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does NKTR pay a dividend?

NKTR's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.